Market Cap 665.72M
Revenue (ttm) 0.00
Net Income (ttm) -51.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,250,100
Avg Vol 1,133,680
Day's Range N/A - N/A
Shares Out 62.16M
Stochastic %K 63%
Beta 3.45
Analysts Strong Sell
Price Target $28.50

Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 561 8600
Address:
155 Bovet Road, Suite 303, San Mateo, United States
shibadad
shibadad Sep. 9 at 9:25 PM
$SGMT Denifanstat's potential in replacing Accutane is astounding. Retail pharmacies dispensed 19.8 million outpatient prescriptions for isotretinoin from marketing in 1982 through 2000. From 1983 through 1993, the median annual number of prescriptions was just over 800,000; between 1992 and 2000, the number of prescriptions increased 2.5-fold (250%) to nearly 2 million in year 2000. (see link for 2002 article). If denifanstat reaches half the number of patients (400k) that Accutane reached in its first decade, the annual revenue is $5B+. This doesn't even take into account that the US population in 1982 was just 230M vs 345M today. https://pubmed.ncbi.nlm.nih.gov/11907498/#:~:text=Results%3A%20Retail%20pharmacies%20dispensed%2019.8%20million%20outpatient,about%20275%25%20increases%20from%201995%20through%201999.
1 · Reply
Expharmaguy
Expharmaguy Sep. 9 at 6:12 PM
$SGMT Lots of garnularity around acne. MASH appears to be dead? no mention.Cantor did not even ask a question. Ascletis approval in China end of yr, or beginning of 1st qtr. Ascletis presenting phase 3 data at European Derm meeting. CEO revealed some preliminary thoughts on pricing. Likely to be higher than $1000-1200 per month. Also very obvious they want to commercialize on their own.
1 · Reply
shibadad
shibadad Sep. 9 at 6:12 PM
$SGMT There was actually a lot of new info today Cantor Fireside Highlights (1/2) : - FDA understood that acne is agnostic to race - FDA asked them to include 12-17 year olds in their P3 trials - will have P2 data on TVB 3567 by end of 2027. - Happel expects deni to be a game changer in acne - Ascletis to provide additional extension data at EADV (end of Sept). Will show continuing improvement in IGA scores. At 52 wks, data will show similar results to Accutane albeit at a slower but much safer pace - quite confident that the extension outcomes and 52 wk will be eye opening - expects to be twice as a effective as any oral antibiotic or topical - payors are comfortable at a premium pricing to current options $1100-1200/month - usage will be heavily influenced by DTC model (social media)
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Sep. 9 at 6:07 PM
$SGMT Approval in China at the end of this year-beg. 2027. Great stuff. Sounds like a home run.
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Sep. 9 at 6:06 PM
$SGMT 10 years of coverage on the base patent on Deni. out to 2037. The second FASN inhibitor out til 2040's.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Sep. 9 at 6:02 PM
$SGMT the dermatology community has already admitted the need to replace the use of antibiotics with a sebum inhibitor not a antiandrogen steriod.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Sep. 9 at 6:00 PM
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Sep. 9 at 5:52 PM
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Sep. 9 at 5:47 PM
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Sep. 9 at 5:46 PM
0 · Reply
Latest News on SGMT
Cantor starts Sagimet at Overweight on potential in acne

2026-09-09T11:40:10.000Z - 1 day ago

Cantor starts Sagimet at Overweight on potential in acne


Sagimet Biosciences advances AURORA clinical trial

2026-08-25T11:40:27.000Z - 16 days ago

Sagimet Biosciences advances AURORA clinical trial


Sagimet Biosciences Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 4 weeks ago

Sagimet Biosciences Quarterly report: Q2 2026


Sagimet Biosciences Earnings release: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 4 weeks ago

Sagimet Biosciences Earnings release: Q2 2026


Sagimet Biosciences joins Russell 3000, Russell 2000 Indexes

2026-06-29T11:30:24.000Z - 2 months ago

Sagimet Biosciences joins Russell 3000, Russell 2000 Indexes


Sagimet Biosciences reports Q1 EPS (33c), consensus (35c)

2026-05-12T11:45:46.000Z - 4 months ago

Sagimet Biosciences reports Q1 EPS (33c), consensus (35c)


Sagimet Biosciences Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 4 months ago

Sagimet Biosciences Quarterly report: Q1 2026


Sagimet Biosciences Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 4 months ago

Sagimet Biosciences Earnings release: Q1 2026


Sagimet Biosciences Transcript: Status update

Apr 30, 2026, 2:00 PM EDT - 4 months ago

Sagimet Biosciences Transcript: Status update


Sagimet Biosciences Slides: Status update

Apr 30, 2026, 2:00 PM EDT - 4 months ago

Sagimet Biosciences Slides: Status update


3 Penny Stocks to Watch Now, 4/28/26

2026-04-28T18:07:00.000Z - 4 months ago

3 Penny Stocks to Watch Now, 4/28/26

HTCO YAAS


Sagimet Biosciences holds a conference call

2026-04-28T17:15:16.000Z - 4 months ago

Sagimet Biosciences holds a conference call


TD Cowen establishes $21 price target for Sagamet Bioscinces

2026-04-28T12:19:03.000Z - 4 months ago

TD Cowen establishes $21 price target for Sagamet Bioscinces


Sagimet Biosciences Provides Strategic and Corporate Updates

Apr 27, 2026, 7:00 AM EDT - 4 months ago

Sagimet Biosciences Provides Strategic and Corporate Updates


Sagimet Biosciences Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Sagimet Biosciences Proxy statement: Proxy filing


Sagimet Biosciences appoints Grauer as Chief Medical Officer

2026-04-20T11:37:22.000Z - 4 months ago

Sagimet Biosciences appoints Grauer as Chief Medical Officer

OMER


Sagimet Biosciences Earnings release: Q4 2025

Mar 11, 2026, 7:00 AM EDT - 6 months ago

Sagimet Biosciences Earnings release: Q4 2025


Sagimet Biosciences Annual report: Q4 2025

Mar 11, 2026, 7:00 AM EDT - 6 months ago

Sagimet Biosciences Annual report: Q4 2025


Sagimet Biosciences Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 10 months ago

Sagimet Biosciences Earnings release: Q3 2025


Sagimet Biosciences Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 10 months ago

Sagimet Biosciences Quarterly report: Q3 2025


Sagimet Biosciences Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Earnings release: Q2 2025


Sagimet Biosciences Quarterly report: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Quarterly report: Q2 2025


Sagimet Biosciences Slides: Investor Presentation

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Slides: Investor Presentation


Sagimet Biosciences Transcript: KOL Event

Jun 16, 2025, 2:00 PM EDT - 1 year ago

Sagimet Biosciences Transcript: KOL Event


Sagimet Biosciences Press release: KOL Event

Jun 16, 2025, 2:00 PM EDT - 1 year ago

Sagimet Biosciences Press release: KOL Event


Sagimet Biosciences Slides: KOL Event

Jun 16, 2025, 2:00 PM EDT - 1 year ago

Sagimet Biosciences Slides: KOL Event


Sagimet Biosciences Slides: Corporate Presentation

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Slides: Corporate Presentation


Sagimet Biosciences Transcript: KOL Event

May 29, 2025, 1:00 PM EDT - 1 year ago

Sagimet Biosciences Transcript: KOL Event


Sagimet Biosciences Slides: KOL Event

May 29, 2025, 1:00 PM EDT - 1 year ago

Sagimet Biosciences Slides: KOL Event


Sagimet Biosciences Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Earnings release: Q1 2025


Sagimet Biosciences Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Quarterly report: Q1 2025


Sagimet Biosciences Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Proxy statement: Proxy Filing


Sagimet Biosciences Earnings release: Q4 2024

Mar 12, 2025, 7:30 AM EDT - 1 year ago

Sagimet Biosciences Earnings release: Q4 2024


Sagimet Biosciences Annual report: Q4 2024

Mar 12, 2025, 7:30 AM EDT - 1 year ago

Sagimet Biosciences Annual report: Q4 2024


Sagimet Biosciences Earnings release: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Sagimet Biosciences Earnings release: Q3 2024


Sagimet Biosciences Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Sagimet Biosciences Quarterly report: Q3 2024


Sagimet Biosciences Registration statement: Registration Filing

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Registration statement: Registration Filing


Sagimet Biosciences Quarterly report: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Quarterly report: Q2 2024


Sagimet Biosciences Earnings release: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Earnings release: Q2 2024


Sagimet Biosciences Transcript: Study Update

Jun 13, 2024, 12:30 PM EDT - 2 years ago

Sagimet Biosciences Transcript: Study Update


Sagimet Biosciences Press release: Study Update

Jun 13, 2024, 12:30 PM EDT - 2 years ago

Sagimet Biosciences Press release: Study Update


Sagimet Biosciences Slides: Study Update

Jun 13, 2024, 12:30 PM EDT - 2 years ago

Sagimet Biosciences Slides: Study Update


Sagimet Biosciences Transcript: Investor & Analyst Day 2024

May 23, 2024, 1:00 PM EDT - 2 years ago

Sagimet Biosciences Transcript: Investor & Analyst Day 2024


Sagimet Biosciences Slides: FY 2024

May 23, 2024, 1:00 PM EDT - 2 years ago

Sagimet Biosciences Slides: FY 2024


shibadad
shibadad Sep. 9 at 9:25 PM
$SGMT Denifanstat's potential in replacing Accutane is astounding. Retail pharmacies dispensed 19.8 million outpatient prescriptions for isotretinoin from marketing in 1982 through 2000. From 1983 through 1993, the median annual number of prescriptions was just over 800,000; between 1992 and 2000, the number of prescriptions increased 2.5-fold (250%) to nearly 2 million in year 2000. (see link for 2002 article). If denifanstat reaches half the number of patients (400k) that Accutane reached in its first decade, the annual revenue is $5B+. This doesn't even take into account that the US population in 1982 was just 230M vs 345M today. https://pubmed.ncbi.nlm.nih.gov/11907498/#:~:text=Results%3A%20Retail%20pharmacies%20dispensed%2019.8%20million%20outpatient,about%20275%25%20increases%20from%201995%20through%201999.
1 · Reply
Expharmaguy
Expharmaguy Sep. 9 at 6:12 PM
$SGMT Lots of garnularity around acne. MASH appears to be dead? no mention.Cantor did not even ask a question. Ascletis approval in China end of yr, or beginning of 1st qtr. Ascletis presenting phase 3 data at European Derm meeting. CEO revealed some preliminary thoughts on pricing. Likely to be higher than $1000-1200 per month. Also very obvious they want to commercialize on their own.
1 · Reply
shibadad
shibadad Sep. 9 at 6:12 PM
$SGMT There was actually a lot of new info today Cantor Fireside Highlights (1/2) : - FDA understood that acne is agnostic to race - FDA asked them to include 12-17 year olds in their P3 trials - will have P2 data on TVB 3567 by end of 2027. - Happel expects deni to be a game changer in acne - Ascletis to provide additional extension data at EADV (end of Sept). Will show continuing improvement in IGA scores. At 52 wks, data will show similar results to Accutane albeit at a slower but much safer pace - quite confident that the extension outcomes and 52 wk will be eye opening - expects to be twice as a effective as any oral antibiotic or topical - payors are comfortable at a premium pricing to current options $1100-1200/month - usage will be heavily influenced by DTC model (social media)
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Sep. 9 at 6:07 PM
$SGMT Approval in China at the end of this year-beg. 2027. Great stuff. Sounds like a home run.
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Sep. 9 at 6:06 PM
$SGMT 10 years of coverage on the base patent on Deni. out to 2037. The second FASN inhibitor out til 2040's.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Sep. 9 at 6:02 PM
$SGMT the dermatology community has already admitted the need to replace the use of antibiotics with a sebum inhibitor not a antiandrogen steriod.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Sep. 9 at 6:00 PM
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Sep. 9 at 5:52 PM
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Sep. 9 at 5:47 PM
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Sep. 9 at 5:46 PM
0 · Reply
rational1
rational1 Sep. 9 at 4:19 PM
$SGMT Cantor initiates coverage today. 92 page report. https://my.apps.factset.com/viewer-fusion/?_doc_id=7d2a6ed3c55df6b0a8e40afda49efbd4&_doc_date=20260909&_doc_product=FRC&_doc_docfn=U2FsdGVkX1+eoJnT+J+at1zAJuh6cpxMhXZ5r5qy0t3Zjth7+zHky9RydsKdGrqZkwnnbDbM06B9Uo4Joiq9jzOMs2KaLG+ODTE+2TFxPY0=&_doc_title=A%20Mispriced%20Oral-acne%20Story%20That%20is%20Gaining%20Traction;%20Upcoming%20OLE%20data%20Should%20Further%20Cement%20Denifanstat%27s%20Differentiated%20Profile;%20Initiating%20at%20OW%20(Cantor%20Fitzgerald)%2091%20pages&_doc_search=patient&_app_id=NRFNewsDashboard&_appSesGUID
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Sep. 9 at 2:54 PM
$SGMT she is stealing my thunder-LOL!
0 · Reply
anachartanalyst
anachartanalyst Sep. 9 at 2:02 PM
$SGMT https://anachart.com/wp-content/uploads/2026/09/1788962496_soc-img.jpg
1 · Reply
shibadad
shibadad Sep. 9 at 1:01 PM
$SGMT There's a fireside chat at 1:35pm today at the Cantor Fitz Global Healthcare Conference (link on the website). Not expecting any new news but there's a higher level of awareness among institutional investors this time around. The chat serves to elevate their profile.
0 · Reply
notreload_ai
notreload_ai Sep. 9 at 11:03 AM
Barclays says $SGMT dermatology-first plan is smart. China data may de-risk the U.S. Phase 3 readout expected by the end of 2027. https://notreload.xyz/xy/barclays-lifts-sagimet-target-to-18-on-acne-drug/
0 · Reply
shibadad
shibadad Sep. 8 at 2:59 PM
$SGMT A lot of volume on Friday especially before the long Labor Day weekend. Would seem to bode well but $11 is really proving to be a stubborn resistance level. Can't quite seem to sustain any kind of momentum above there or close above it. Continued failure would not be a good signal.
1 · Reply
shibadad
shibadad Sep. 4 at 2:12 PM
$SGMT Looks like I made a mistake in estimating when the NMPA window opens for ASC40. 200 workings days from Dec 10, 2025 is Sep 29 not Oct 22 as I previously estimated. I double counted some holidays which are actually weekends and China apparently also has make up days (weekends which are actually workdays). So whomever sold those Oct 10 straddles might want to consider closing that trade before then.
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Sep. 3 at 12:45 PM
$SGMT maybe the MM is considering that the MC is too low and should be closer to 1B, which should value the shares around 16-18
0 · Reply
Geohotventures
Geohotventures Sep. 2 at 10:00 PM
0 · Reply
shibadad
shibadad Sep. 2 at 8:24 PM
$SGMT After some low volume days of consolidation, some large late day buying pushed us to a new post-secondary high close on strong volume. This could be the signal that consolidation is over and we're ready to head higher.
1 · Reply
SecretTradingTips
SecretTradingTips Sep. 2 at 8:06 PM
0 · Reply
shibadad
shibadad Sep. 2 at 2:16 PM
$SGMT Mark your calendars. https://ir.sagimet.com/news-releases/news-release-details/sagimet-biosciences-announces-participation-two-upcoming-0
1 · Reply